# A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

> **NCT06045221** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1698 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT06045221
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-22
- **Primary completion:** 2025-08-22
- **Final completion:** 2025-08-22
- **Target enrollment:** 1698 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045221, "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06045221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*